Get started
Work

P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227

Year: 2023
Type: article
DOI: 10.1016/j.jtho.2023.09.555
Authors: M. Reck, G. Worthy, Y. Yuan, J.R. Penrod, R. Lawrance, F. Taylor, S.I. Blum, A. Moisei, A. Lee, T.-E. Ciuleanu, A. Pluzanski, J.-S. Lee, S. Ramalingam, H. Borghaei, K. O’Byrne, L. Paz-Ares, L. Li, R.G. Gupta, J. Bushong, J. Brahmer
Institutions: German Center for Lung Research, LungenClinic Grosshansdorf, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (United Kingdom), Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, The Maria Sklodowska-Curie National Research Institute of Oncology, Seoul National University Bundang Hospital, Emory University, Winship Cancer Institute, Fox Chase Cancer Center, Translational Research Institute, Queensland University of Technology, Princess Alexandra Hospital, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Johns Hopkins University
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4388045371
FWCI:
Cites:
Cited by:
Related to: 10